News Reader
01-18-2009, 08:23 PM
The U.S. Food and Drug Administration today licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding.
More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01948.html)
More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01948.html)